From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases.
Autoimmune disease
Immune checkpoint
Immune regulation
LAG3
Therapy
Journal
Inflammation research : official journal of the European Histamine Research Society ... [et al.]
ISSN: 1420-908X
Titre abrégé: Inflamm Res
Pays: Switzerland
ID NLM: 9508160
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
12
01
2023
accepted:
12
05
2023
revised:
12
01
2023
medline:
21
6
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
Immune checkpoints negatively regulate immune response, thereby playing an important role in maintaining immune homeostasis. Substantial studies have confirmed that blockade or deficiency of immune checkpoint pathways contributes to the deterioration of autoimmune diseases. In this context, focusing on immune checkpoints might provide alternative strategies for the treatment of autoimmunity. Lymphocyte activation gene 3 (LAG3), as a member of immune checkpoint, is critical in regulating immune responses as manifested in multiple preclinical studies and clinical trials. Recent success of dual-blockade of LAG3 and programmed death-1 in melanoma also supports the notion that LAG3 is a crucial regulator in immune tolerance. We wrote this review article by searching the PubMed, Web of Science and Google Scholar databases. In this review, we summarize the molecular structure and the action mechanisms of LAG3. Additionally, we highlight its roles in diverse autoimmune diseases and discuss how the manipulation of the LAG3 pathway can serve as a promising therapeutic strategy as well as its specific mechanism with the aim of filling the gaps from bench to bedside.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoints negatively regulate immune response, thereby playing an important role in maintaining immune homeostasis. Substantial studies have confirmed that blockade or deficiency of immune checkpoint pathways contributes to the deterioration of autoimmune diseases. In this context, focusing on immune checkpoints might provide alternative strategies for the treatment of autoimmunity. Lymphocyte activation gene 3 (LAG3), as a member of immune checkpoint, is critical in regulating immune responses as manifested in multiple preclinical studies and clinical trials. Recent success of dual-blockade of LAG3 and programmed death-1 in melanoma also supports the notion that LAG3 is a crucial regulator in immune tolerance.
METHODS
METHODS
We wrote this review article by searching the PubMed, Web of Science and Google Scholar databases.
CONCLUSION
CONCLUSIONS
In this review, we summarize the molecular structure and the action mechanisms of LAG3. Additionally, we highlight its roles in diverse autoimmune diseases and discuss how the manipulation of the LAG3 pathway can serve as a promising therapeutic strategy as well as its specific mechanism with the aim of filling the gaps from bench to bedside.
Identifiants
pubmed: 37314518
doi: 10.1007/s00011-023-01742-y
pii: 10.1007/s00011-023-01742-y
doi:
Substances chimiques
Lymphocyte Activation Gene 3 Protein
0
Antigens, CD
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1215-1235Subventions
Organisme : National Natural Science Foundation of China
ID : 81901660
Organisme : China Scholarship Council
ID : 201808330646
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119–25.
pubmed: 12848952
doi: 10.1016/S1568-9972(03)00006-5
Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol. 2017;410:75–97.
pubmed: 28929192
Schnell A, Bod L, Madi A, Kuchroo VK. The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. Cell Res. 2020;30(4):285–99.
pubmed: 31974523
pmcid: 7118128
doi: 10.1038/s41422-020-0277-x
Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6(6):865–71.
pubmed: 32297899
doi: 10.1001/jamaoncol.2020.0726
Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–9.
pubmed: 21739672
doi: 10.1038/ni.2035
Carney EF. Immunology: T-cell exhaustion limits immune reactivity and is associated with good prognosis in autoimmune disease. Nat Rev Nephrol. 2015;11(9):503.
pubmed: 26168738
doi: 10.1038/nrneph.2015.115
Joller N, Kuchroo VK. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol. 2017;410:127–56.
pubmed: 28900677
pmcid: 5902028
Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425–34.
pubmed: 31611702
doi: 10.1038/s41590-019-0512-0
Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.
pubmed: 31690319
pmcid: 6833286
doi: 10.1186/s12943-019-1091-2
Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor. Semin Immunol. 2019;42: 101305.
pubmed: 31604537
pmcid: 6920665
doi: 10.1016/j.smim.2019.101305
Zhang Q, Chikina M, Szymczak-Workman AL, Horne W, Kolls JK, Vignali KM, et al. LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol. 2017. https://doi.org/10.1126/sciimmunol.aah4569 .
doi: 10.1126/sciimmunol.aah4569
pubmed: 29196450
pmcid: 7847246
Zhang Q, Vignali DA. Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity. 2016;44(5):1034–51.
pubmed: 27192568
pmcid: 4873959
doi: 10.1016/j.immuni.2016.04.017
Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171(5):1393–405.
pubmed: 1692078
doi: 10.1084/jem.171.5.1393
Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol. 1995;25(9):2718–21.
pubmed: 7589152
doi: 10.1002/eji.1830250949
Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci USA. 1997;94(11):5744–9.
pubmed: 9159144
pmcid: 20850
doi: 10.1073/pnas.94.11.5744
Mastrangeli R, Micangeli E, Donini S. Cloning of murine LAG-3 by magnetic bead bound homologous probes and PCR (gene-capture PCR). Anal Biochem. 1996;241(1):93–102.
pubmed: 8921170
doi: 10.1006/abio.1996.0382
Li N, Wang Y, Forbes K, Vignali KM, Heale BS, Saftig P, et al. Metalloproteases regulate T-cell proliferation and effector function via LAG-3. Embo J. 2007;26(2):494–504.
pubmed: 17245433
pmcid: 1783452
doi: 10.1038/sj.emboj.7601520
Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol. 2003;33(4):970–9.
pubmed: 12672063
doi: 10.1002/eji.200323382
Hu S, Liu X, Li T, Li Z, Hu F. LAG3 (CD223) and autoimmunity: emerging evidence. J Autoimmun. 2020;112: 102504.
pubmed: 32576412
doi: 10.1016/j.jaut.2020.102504
Maeda TK, Sugiura D, Okazaki IM, Maruhashi T, Okazaki T. Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation. J Biol Chem. 2019;294(15):6017–26.
pubmed: 30760527
pmcid: 6463702
doi: 10.1074/jbc.RA119.007455
Workman CJ, Dugger KJ, Vignali DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol. 2002;169(10):5392–5.
pubmed: 12421911
doi: 10.4049/jimmunol.169.10.5392
Iouzalen N, Andreae S, Hannier S, Triebel F. LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway. Eur J Immunol. 2001;31(10):2885–91.
pubmed: 11592063
doi: 10.1002/1521-4141(2001010)31:10<2885::AID-IMMU2885>3.0.CO;2-2
Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology. 2005;115(2):170–8.
pubmed: 15885122
pmcid: 1782137
doi: 10.1111/j.1365-2567.2005.02145.x
Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol. 2011;186(9):5173–83.
pubmed: 21441454
doi: 10.4049/jimmunol.1002050
Shan C, Li X, Zhang J. Progress of immune checkpoint LAG-3 in immunotherapy. Oncol Lett. 2020;20(5):207.
pubmed: 32963613
pmcid: 7491111
doi: 10.3892/ol.2020.12070
Dong Y, Li X, Zhang L, Zhu Q, Chen C, Bao J, et al. CD4(+) T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B. BMC Immunol. 2019;20(1):27.
pubmed: 31390978
pmcid: 6686459
doi: 10.1186/s12865-019-0309-9
Bae J, Hideshima T, Zhang GL, Zhou J, Keskin DB, Munshi NC, et al. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Leukemia. 2018;32(3):752–64.
pubmed: 29089645
doi: 10.1038/leu.2017.316
Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503–13.
pubmed: 15485628
doi: 10.1016/j.immuni.2004.08.010
Zhou X, Ren T, Zan H, Hua C, Guo X. Novel immune checkpoints in esophageal cancer: from biomarkers to therapeutic targets. Front Immunol. 2022;13: 864202.
pubmed: 35669786
pmcid: 9163322
doi: 10.3389/fimmu.2022.864202
Huard B, Tournier M, Triebel F. LAG-3 does not define a specific mode of natural killing in human. Immunol Lett. 1998;61(2–3):109–12.
pubmed: 9657262
doi: 10.1016/S0165-2478(97)00170-3
Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol. 2005;35(7):2081–8.
pubmed: 15971272
doi: 10.1002/eji.200526090
Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016. https://doi.org/10.1126/science.aah3374 .
doi: 10.1126/science.aah3374
pubmed: 27934760
pmcid: 5510615
Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208(2):395–407.
pubmed: 21300912
pmcid: 3039848
doi: 10.1084/jem.20100466
Bruniquel D, Borie N, Hannier S, Triebel F. Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II. Immunogenetics. 1998;48(2):116–24.
pubmed: 9634475
doi: 10.1007/s002510050411
Do JS, Visperas A, Sanogo YO, Bechtel JJ, Dvorina N, Kim S, et al. An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy. Mucosal Immunol. 2016;9(1):137–45.
pubmed: 26013006
doi: 10.1038/mi.2015.45
Sun H, Sun C, Xiao W. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. Cytokine. 2014;65(1):33–41.
pubmed: 24139237
doi: 10.1016/j.cyto.2013.09.016
Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571(7764):211–8.
pubmed: 31207603
pmcid: 6713202
doi: 10.1038/s41586-019-1325-x
Martinez GJ, Pereira RM, Äijö T, Kim EY, Marangoni F, Pipkin ME, et al. The transcription factor NFAT promotes exhaustion of activated CD8
pubmed: 25680272
pmcid: 4346317
doi: 10.1016/j.immuni.2015.01.006
Rudd CE, Chanthong K, Taylor A. Small molecule inhibition of GSK-3 specifically inhibits the transcription of inhibitory co-receptor LAG-3 for enhanced anti-tumor immunity. Cell Rep. 2020;30(7):2075-82.e4.
pubmed: 32075731
doi: 10.1016/j.celrep.2020.01.076
Klümper N, Ralser DJ, Bawden EG, Landsberg J, Zarbl R, Kristiansen G, et al. LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. J Immunother Cancer. 2020;8(1):e000552.
pubmed: 32234847
pmcid: 7174079
doi: 10.1136/jitc-2020-000552
Woo SR, Li N, Bruno TC, Forbes K, Brown S, Workman C, et al. Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol. 2010;40(6):1768–77.
pubmed: 20391435
pmcid: 2987677
doi: 10.1002/eji.200939874
Marion S, Fralish GB, Laporte S, Caron MG, Barak LS. N-terminal tyrosine modulation of the endocytic adaptor function of the beta-arrestins. J Biol Chem. 2007;282(26):18937–44.
pubmed: 17456469
doi: 10.1074/jbc.M700090200
Moss ML, Minond D. Recent advances in ADAM17 research: a promising target for cancer and inflammation. Mediat Inflamm. 2017;2017:9673537.
doi: 10.1155/2017/9673537
Andrews LP, Somasundaram A, Moskovitz JM, Szymczak-Workman AL, Liu C, Cillo AR, et al. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020. https://doi.org/10.1126/sciimmunol.abc2728 .
doi: 10.1126/sciimmunol.abc2728
pubmed: 32709702
pmcid: 8581949
Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80–96.
pubmed: 28258692
pmcid: 5338468
doi: 10.1111/imr.12519
Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DA. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol. 2002;32(8):2255–63.
pubmed: 12209638
doi: 10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A
Maruhashi T, Okazaki IM, Sugiura D, Takahashi S, Maeda TK, Shimizu K, et al. LAG-3 inhibits the activation of CD4(+) T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nat Immunol. 2018;19(12):1415–26.
pubmed: 30349037
doi: 10.1038/s41590-018-0217-9
MacLachlan BJ, Mason GH, Greenshields-Watson A, Triebel F, Gallimore A, Cole DK, et al. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. Eur J Immunol. 2021;51(2):331–41.
pubmed: 32920841
doi: 10.1002/eji.202048753
Buisson S, Triebel F. LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors. Immunology. 2005;114(3):369–74.
pubmed: 15720438
pmcid: 1782096
doi: 10.1111/j.1365-2567.2004.02087.x
Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015;3(4):412–23.
pubmed: 25691328
pmcid: 4390508
doi: 10.1158/2326-6066.CIR-14-0150
Chung LY, Tang SJ, Wu YC, Sun GH, Liu HY, Sun KH. Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin. Oncotarget. 2015;6(7):4936–52.
pubmed: 25669973
doi: 10.18632/oncotarget.3210
Li M, Feng YM, Fang SQ. Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer. Braz J Med Biol Res. 2017;50(4): e5356.
pubmed: 28355349
pmcid: 5423742
doi: 10.1590/1414-431x20165356
Lu W, Wang J, Yang G, Yu N, Huang Z, Xu H, et al. Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression. Oncotarget. 2017;8(9):15242–51.
pubmed: 28146425
pmcid: 5362483
doi: 10.18632/oncotarget.14839
Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176(1–2):334-47.e12.
pubmed: 30580966
doi: 10.1016/j.cell.2018.11.010
Sun C, Gao W, Liu J, Cheng H, Hao J. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir Res. 2020;21(1):210.
pubmed: 32778129
pmcid: 7418324
doi: 10.1186/s12931-020-01477-y
Guo M, Yuan F, Qi F, Sun J, Rao Q, Zhao Z, et al. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8(+)T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med. 2020;18(1):306.
pubmed: 32762721
pmcid: 7409704
doi: 10.1186/s12967-020-02469-8
Liu W, Tang L, Zhang G, Wei H, Cui Y, Guo L, et al. Characterization of a novel C-type lectin-like gene, LSECtin: demonstration of carbohydrate binding and expression in sinusoidal endothelial cells of liver and lymph node. J Biol Chem. 2004;279(18):18748–58.
pubmed: 14711836
doi: 10.1074/jbc.M311227200
Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 2014;74(13):3418–28.
pubmed: 24769443
doi: 10.1158/0008-5472.CAN-13-2690
Hannier S, Triebel F. The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes. Int Immunol. 1999;11(11):1745–52.
pubmed: 10545478
doi: 10.1093/intimm/11.11.1745
Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol. 1998;161(8):4058–65.
pubmed: 9780176
doi: 10.4049/jimmunol.161.8.4058
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
pubmed: 18173375
doi: 10.1146/annurev.immunol.26.021607.090331
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.
pubmed: 22150039
doi: 10.1056/NEJMra1004965
Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–61.
pubmed: 12748655
doi: 10.1038/nature01661
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–108.
pubmed: 20870100
doi: 10.1016/S0140-6736(10)60826-4
Conigliaro P, Chimenti MS, Triggianese P, Sunzini F, Novelli L, Perricone C, et al. Autoantibodies in inflammatory arthritis. Autoimmun Rev. 2016;15(7):673–83.
pubmed: 26970491
doi: 10.1016/j.autrev.2016.03.003
Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636–45.
pubmed: 19464986
doi: 10.1016/j.immuni.2009.04.010
Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180(9):5916–26.
pubmed: 18424711
doi: 10.4049/jimmunol.180.9.5916
Oh S, Rankin AL, Caton AJ. CD4+CD25+ regulatory T cells in autoimmune arthritis. Immunol Rev. 2010;233(1):97–111.
pubmed: 20192995
pmcid: 2908310
doi: 10.1111/j.0105-2896.2009.00848.x
Meng HX, Cao Y, Zhang SQ, Bi ZG, Yamakawa M. Distribution of regulatory T cells and interaction with dendritic cells in the synovium of rheumatoid arthritis. Scand J Rheumatol. 2012;41(6):413–20.
pubmed: 23157225
doi: 10.3109/03009742.2012.696135
Nakachi S, Sumitomo S, Tsuchida Y, Tsuchiya H, Kono M, Kato R, et al. Interleukin-10-producing LAG3(+) regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):97.
pubmed: 28511719
pmcid: 5434528
doi: 10.1186/s13075-017-1309-x
Saadati N, Khodashahi M, Rezaieyazdi Z, Sahebari M, Saremi Z, Mohammadian Haftcheshmeh S, et al. Serum level of soluble lymphocyte-activation gene 3 is increased in patients with rheumatoid arthritis. Iran J Immunol. 2020;17(4):324–32.
pubmed: 33382389
Chen PM, Tsokos GC. The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update. Curr Opin Rheumatol. 2021;33(6):586–91.
pubmed: 34183542
pmcid: 8567317
doi: 10.1097/BOR.0000000000000815
Szelinski F, Lino AC, Dörner T. B cells in systemic lupus erythematosus. Curr Opin Rheumatol. 2022;34(2):125–32.
pubmed: 34939607
doi: 10.1097/BOR.0000000000000865
Klarquist J, Zhou Z, Shen N, Janssen EM. Dendritic Cells in systemic lupus erythematosus: from pathogenic players to therapeutic tools. Mediat Inflamm. 2016;2016:5045248.
doi: 10.1155/2016/5045248
Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol. 2022;18(3):146–57.
pubmed: 35039665
doi: 10.1038/s41584-021-00739-3
Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013;14(4):307–8.
pubmed: 23507634
doi: 10.1038/ni.2554
Li MO, Rudensky AY. T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat Rev Immunol. 2016;16(4):220–33.
pubmed: 27026074
pmcid: 4968889
doi: 10.1038/nri.2016.26
Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21(10):1105–11.
pubmed: 19737784
doi: 10.1093/intimm/dxp095
Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci USA. 2009;106(33):13974–9.
pubmed: 19666526
pmcid: 2729005
doi: 10.1073/pnas.0906872106
Tsuchida Y, Sumitomo S, Ishigaki K, Suzuki A, Kochi Y, Tsuchiya H, et al. TGF-β3 inhibits antibody production by human B Cells. PLoS One. 2017;12(1): e0169646.
pubmed: 28052118
pmcid: 5215424
doi: 10.1371/journal.pone.0169646
Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, et al. TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses. Nat Commun. 2015;6:6329.
pubmed: 25695838
doi: 10.1038/ncomms7329
Morita K, Okamura T, Inoue M, Komai T, Teruya S, Iwasaki Y, et al. Egr2 and Egr3 in regulatory T cells cooperatively control systemic autoimmunity through Ltbp3-mediated TGF-β3 production. Proc Natl Acad Sci USA. 2016;113(50):E8131–40.
pubmed: 27911796
pmcid: 5167141
doi: 10.1073/pnas.1611286114
Kato R, Sumitomo S, Tsuchida Y, Tsuchiya H, Nakachi S, Sakurai K, et al. CD4(+)CD25(+)LAG3(+) T cells with a feature of Th17 cells associated with systemic lupus erythematosus disease activity. Front Immunol. 2019;10:1619.
pubmed: 31354747
pmcid: 6640175
doi: 10.3389/fimmu.2019.01619
Lino AC, Dang VD, Lampropoulou V, Welle A, Joedicke J, Pohar J, et al. LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells. Immunity. 2018;49(1):120-33.e9.
pubmed: 30005826
pmcid: 6057275
doi: 10.1016/j.immuni.2018.06.007
Dang VD, Mohr E, Szelinski F, Le TA, Ritter J, Hinnenthal T, et al. CD39 and CD326 are bona fide markers of murine and human plasma cells and identify a bone marrow specific plasma cell subpopulation in lupus. Front Immunol. 2022;13: 873217.
pubmed: 35464469
pmcid: 9024045
doi: 10.3389/fimmu.2022.873217
Peloquin JM, Goel G, Villablanca EJ, Xavier RJ. Mechanisms of pediatric inflammatory bowel disease. Annu Rev Immunol. 2016;34:31–64.
pubmed: 27168239
doi: 10.1146/annurev-immunol-032414-112151
Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology. 2012;136(2):115–22.
pubmed: 22348589
pmcid: 3403270
doi: 10.1111/j.1365-2567.2012.03572.x
Harrison OJ, Powrie FM. Regulatory T cells and immune tolerance in the intestine. Cold Spring Harb Perspect Biol. 2013;5(7):a018341.
pubmed: 23818502
pmcid: 3685893
doi: 10.1101/cshperspect.a018341
Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood. 2006;108(1):253–61.
pubmed: 16537805
pmcid: 1895836
doi: 10.1182/blood-2005-11-4567
Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389(6652):737–42.
pubmed: 9338786
doi: 10.1038/39614
Engelhardt KR, Grimbacher B. IL-10 in humans: lessons from the gut, IL-10/IL-10 receptor deficiencies, and IL-10 polymorphisms. Curr Top Microbiol Immunol. 2014;380:1–18.
pubmed: 25004811
Ahlers J, Mantei A, Lozza L, Stäber M, Heinrich F, Bacher P, et al. A Notch/STAT3-driven Blimp-1/c-Maf-dependent molecular switch induces IL-10 expression in human CD4(+) T cells and is defective in Crohn’s disease patients. Mucosal Immunol. 2022;15(3):480–90.
pubmed: 35169232
pmcid: 9038525
doi: 10.1038/s41385-022-00487-x
Brockmann L, Soukou S, Steglich B, Czarnewski P, Zhao L, Wende S, et al. Molecular and functional heterogeneity of IL-10-producing CD4(+) T cells. Nat Commun. 2018;9(1):5457.
pubmed: 30575716
pmcid: 6303294
doi: 10.1038/s41467-018-07581-4
Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–17.
pubmed: 21677747
pmcid: 3204665
doi: 10.1038/nature10209
Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1(7):553–62.
pubmed: 7600284
doi: 10.1016/1074-7613(94)90045-0
Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34(4):566–78.
pubmed: 21511185
pmcid: 3088485
doi: 10.1016/j.immuni.2011.03.018
Zhu B, Symonds AL, Martin JE, Kioussis D, Wraith DC, Li S, et al. Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease. J Exp Med. 2008;205(10):2295–307.
pubmed: 18779345
pmcid: 2556781
doi: 10.1084/jem.20080187
Myouzen K, Kochi Y, Shimane K, Fujio K, Okamura T, Okada Y, et al. Regulatory polymorphisms in EGR2 are associated with susceptibility to systemic lupus erythematosus. Hum Mol Genet. 2010;19(11):2313–20.
pubmed: 20194224
doi: 10.1093/hmg/ddq092
Holmén N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjövall H, et al. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis. 2006;12(6):447–56.
pubmed: 16775488
doi: 10.1097/00054725-200606000-00003
Nakanishi Y, Ikebuchi R, Chtanova T, Kusumoto Y, Okuyama H, Moriya T, et al. Regulatory T cells with superior immunosuppressive capacity emigrate from the inflamed colon to draining lymph nodes. Mucosal Immunol. 2018;11(2):437–48.
pubmed: 28766553
doi: 10.1038/mi.2017.64
Bauché D, Joyce-Shaikh B, Jain R, Grein J, Ku KS, Blumenschein WM, et al. LAG3(+) regulatory T cells restrain interleukin-23-producing CX3CR1(+) gut-resident macrophages during group 3 innate lymphoid cell-driven colitis. Immunity. 2018;49(2):342–52 (e5).
pubmed: 30097293
doi: 10.1016/j.immuni.2018.07.007
Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):3–10.
pubmed: 23774107
doi: 10.1016/j.autrev.2013.06.004
Cheroutre H, Lambolez F. Doubting the TCR coreceptor function of CD8alphaalpha. Immunity. 2008;28(2):149–59.
pubmed: 18275828
doi: 10.1016/j.immuni.2008.01.005
Zhao D, Xu A, Dai Z, Peng J, Zhu M, Shen J, et al. WNT5A transforms intestinal CD8αα
pubmed: 26652024
pmcid: 4676129
doi: 10.1186/s12876-015-0402-3
Slevin SM, Garner LC, Lahiff C, Tan M, Wang LM, Ferry H, et al. Lymphocyte activation gene (LAG)-3 is associated with mucosal inflammation and disease activity in ulcerative colitis. J Crohns Colitis. 2020;14(10):1446–61.
pubmed: 32179884
pmcid: 7533903
doi: 10.1093/ecco-jcc/jjaa054
Lushnikova A, Bohr J, Wickbom A, Münch A, Sjöberg K, Hultgren O, et al. Patients with microscopic colitis have altered levels of inhibitory and stimulatory biomarkers in colon biopsies and sera compared to non-inflamed controls. Front Med (Lausanne). 2021;8: 727412.
pubmed: 34722568
doi: 10.3389/fmed.2021.727412
Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin N Am. 2010;39(3):481–97.
doi: 10.1016/j.ecl.2010.05.011
Zhao H, Karman J, Jiang JL, Zhang J, Gumlaw N, Lydon J, et al. A bispecific protein capable of engaging CTLA-4 and MHCII protects non-obese diabetic mice from autoimmune diabetes. PLoS One. 2013;8(5): e63530.
pubmed: 23704916
pmcid: 3660570
doi: 10.1371/journal.pone.0063530
Grebinoski S, Zhang Q, Cillo AR, Manne S, Xiao H, Brunazzi EA, et al. Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat Immunol. 2022;23(6):868–77.
pubmed: 35618829
pmcid: 9179227
doi: 10.1038/s41590-022-01210-5
Anderson MS, Su MA. AIRE expands: new roles in immune tolerance and beyond. Nat Rev Immunol. 2016;16(4):247–58.
pubmed: 26972725
pmcid: 4831132
doi: 10.1038/nri.2016.9
Li D, Li H, Fu H, Niu K, Guo Y, Guo C, et al. Aire-Overexpressing Dendritic Cells Induce Peripheral CD4+ T Cell Tolerance. Int J Mol Sci. 2015;17(1):38.
pubmed: 26729097
pmcid: 4730283
doi: 10.3390/ijms17010038
Lundmark F, Harbo HF, Celius EG, Saarela J, Datta P, Oturai A, et al. Association analysis of the LAG3 and CD4 genes in multiple sclerosis in two independent populations. J Neuroimmunol. 2006;180(1–2):193–8.
pubmed: 17020785
doi: 10.1016/j.jneuroim.2006.08.009
Jones BE, Maerz MD, Bahnson HT, Somasundaram A, McCarthy LH, Speake C, et al. Fewer LAG-3 T cells in relapsing-remitting multiple sclerosis and type 1 diabetes. J Immunol. 2022;208(3):594–602.
pubmed: 35022272
doi: 10.4049/jimmunol.2100850
Khsheibun R, Paperna T, Volkowich A, Lejbkowicz I, Avidan N, Miller A. Gene expression profiling of the response to interferon beta in Epstein–Barr-transformed and primary B cells of patients with multiple sclerosis. PLoS One. 2014;9(7): e102331.
pubmed: 25025430
pmcid: 4099420
doi: 10.1371/journal.pone.0102331
Nuro-Gyina PK, Rieser EL, Granitto MC, Pei W, Liu Y, Lee PW, et al. Regulation of effector function of CNS autoreactive CD4 T cells through inhibitory receptors and IL-7Rα. J Neuroinflamm. 2016;13(1):302.
doi: 10.1186/s12974-016-0768-3
Kadowaki A, Saga R, Lin Y, Sato W, Yamamura T. Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis. Brain. 2019;142(4):916–31.
pubmed: 30770703
pmcid: 6439331
doi: 10.1093/brain/awz012
Lavon I, Heli C, Brill L, Charbit H, Vaknin-Dembinsky A. Blood levels of co-inhibitory-receptors: a biomarker of disease prognosis in multiple sclerosis. Front Immunol. 2019;10:835.
pubmed: 31134049
pmcid: 6524709
doi: 10.3389/fimmu.2019.00835
Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–55.
pubmed: 24655295
pmcid: 4229247
doi: 10.1146/annurev-immunol-032713-120225
Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015;7(269):269rv1.
pubmed: 25568072
pmcid: 4425129
doi: 10.1126/scitranslmed.3010641
Sheng Y, Jin X, Xu J, Gao J, Du X, Duan D, et al. Sequencing-based approach identified three new susceptibility loci for psoriasis. Nat Commun. 2014;5:4331.
pubmed: 25006012
doi: 10.1038/ncomms5331
Kim J, Lee J, Gonzalez J, Fuentes-Duculan J, Garcet S, Krueger JG. Proportion of CD4CD49bLAG-3 type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index. J Investig Dermatol. 2018;138(12):2669–72.
pubmed: 29890167
doi: 10.1016/j.jid.2018.05.021
Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643–56.
pubmed: 30354958
pmcid: 6467577
doi: 10.1056/NEJMra1413485
Sun Y, Liu C, Jiao T, Xie N, Wang H, Qi W, et al. Decreased LAG3 expression on T effector cells and regulatory T cells in SAA. Int J Hematol. 2020;112(6):757–63.
pubmed: 32785818
doi: 10.1007/s12185-020-02966-y
Gong B, Wang C, Meng F, Wang H, Song B, Yang Y, et al. Association between gut microbiota and autoimmune thyroid disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12: 774362.
pubmed: 34867823
doi: 10.3389/fendo.2021.774362
Vitales-Noyola M, Serrano-Somavilla A, Martínez-Hernández R, Sampedro-Nuñez M, Ramos-Levi AM, González-Amaro R, et al. Patients with autoimmune thyroiditis show diminished levels and defective suppressive function of Tr1 regulatory lymphocytes. J Clin Endocrinol Metab. 2018;103(9):3359–67.
pubmed: 29982465
doi: 10.1210/jc.2018-00498
Horai R, Caspi RR. Microbiome and autoimmune uveitis. Front Immunol. 2019;10:232.
pubmed: 30837991
pmcid: 6389708
doi: 10.3389/fimmu.2019.00232
Raverdeau M, Christofi M, Malara A, Wilk MM, Misiak A, Kuffova L, et al. Retinoic acid-induced autoantigen-specific type 1 regulatory T cells suppress autoimmunity. EMBO Rep. 2019. https://doi.org/10.15252/embr.201847121 .
doi: 10.15252/embr.201847121
pubmed: 30894405
pmcid: 6500997
Dorshkind K, Montecino-Rodriguez E. Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. Nat Rev Immunol. 2007;7(3):213–9.
pubmed: 17318232
doi: 10.1038/nri2019
Choi JK, Yu CR, Bing SJ, Jittayasothorn Y, Mattapallil MJ, Kang M, et al. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. Proc Natl Acad Sci USA. 2021. https://doi.org/10.1073/pnas.2109548118 .
doi: 10.1073/pnas.2109548118
pubmed: 34903665
pmcid: 8740718
Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol. 2004;172(9):5450–5.
pubmed: 15100286
doi: 10.4049/jimmunol.172.9.5450
Kadowaki A, Miyake S, Saga R, Chiba A, Mochizuki H, Yamamura T. Gut environment-induced intraepithelial autoreactive CD4(+) T cells suppress central nervous system autoimmunity via LAG-3. Nat Commun. 2016;7:11639.
pubmed: 27198196
pmcid: 4876462
doi: 10.1038/ncomms11639
Shao TY, Hsu LH, Chien CH, Chiang BL. Novel Foxp3(-) IL-10(-) regulatory T-cells induced by B-cells alleviate intestinal inflammation in vivo. Sci Rep. 2016;6:32415.
pubmed: 27581189
pmcid: 5007537
doi: 10.1038/srep32415
Chen X, Oppenheim JJ. Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells. Int Immunopharmacol. 2011;11(10):1489–96.
pubmed: 21635972
pmcid: 3183123
doi: 10.1016/j.intimp.2011.05.018
Fujio K, Okamura T, Yamamoto K. The family of IL-10-secreting CD4+ T cells. Adv Immunol. 2010;105:99–130.
pubmed: 20510731
doi: 10.1016/S0065-2776(10)05004-2
Chen SY, Hsu WT, Chen YL, Chien CH, Chiang BL. Lymphocyte-activation gene 3(+) (LAG3(+)) forkhead box protein 3(-) (FOXP3(-)) regulatory T cells induced by B cells alleviates joint inflammation in collagen-induced arthritis. J Autoimmun. 2016;68:75–85.
pubmed: 26908164
doi: 10.1016/j.jaut.2016.02.002
Lin WW, Ho KW, Su HH, Fang TF, Tzou SC, Chen IJ, et al. Fibrinogen-like protein 1 serves as an anti-inflammatory agent for collagen-induced arthritis therapy in mice. Front Immunol. 2021;12: 767868.
pubmed: 34975855
pmcid: 8716738
doi: 10.3389/fimmu.2021.767868
Koga MM, Engel A, Pigni M, Lavanchy C, Stevanin M, Laversenne V, et al. IL10- and IL35-secreting MutuDC lines act in cooperation to inhibit memory T cell activation through LAG-3 expression. Front Immunol. 2021;12: 607315.
pubmed: 33679743
pmcid: 7925845
doi: 10.3389/fimmu.2021.607315
Hall AO, Silver JS, Hunter CA. The immunobiology of IL-27. Adv Immunol. 2012;115:1–44.
pubmed: 22608254
doi: 10.1016/B978-0-12-394299-9.00001-1
Beizavi Z, Zohouri M, Asadipour M, Ghaderi A. IL-27, a pleiotropic cytokine for fine-tuning the immune response in cancer. Int Rev Immunol. 2021;40(5):319–29.
pubmed: 33146571
doi: 10.1080/08830185.2020.1840565
Hanson ML, Hixon JA, Li W, Felber BK, Anver MR, Stewart CA, et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology. 2014;146(1):210-21.e13.
pubmed: 24120477
doi: 10.1053/j.gastro.2013.09.060
Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, et al. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol. 2011;300(4):G568–76.
pubmed: 21193526
doi: 10.1152/ajpgi.00329.2010
Visperas A, Do JS, Bulek K, Li X, Min B. IL-27, targeting antigen-presenting cells, promotes Th17 differentiation and colitis in mice. Mucosal Immunol. 2014;7(3):625–33.
pubmed: 24129161
doi: 10.1038/mi.2013.82
Ellis J, Srinivasan N, Barrett C, Hopkins TG, Richards A, et al. Depletion of LAG-3(+) T cells translated to pharmacology and improvement in psoriasis disease activity: a phase I randomized study of mAb GSK2831781. Clin Pharmacol Ther. 2021;109(5):1293–303.
pubmed: 33113155
doi: 10.1002/cpt.2091
Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115(Pt 19):3719–27.
pubmed: 12235282
doi: 10.1242/jcs.00063
Triebel F, Hacene K, Pichon MF. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett. 2006;235(1):147–53.
pubmed: 15946792
doi: 10.1016/j.canlet.2005.04.015
Delmastro MM, Styche AJ, Trucco MM, Workman CJ, Vignali DA, Piganelli JD. Modulation of redox balance leaves murine diabetogenic TH1 T cells “LAG-3-ing” behind. Diabetes. 2012;61(7):1760–8.
pubmed: 22586584
pmcid: 3379669
doi: 10.2337/db11-1591
Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis. Drugs. 2017;77(11):1221–33.
pubmed: 28608166
doi: 10.1007/s40265-017-0775-4
Alenazy MF, Saheb Sharif-Askari F, Omair MA, El-Wetidy MS, Omair MA, Mitwalli H, et al. Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance. Sci Rep. 2021;11(1):5629.
pubmed: 33707483
pmcid: 7952390
doi: 10.1038/s41598-021-83615-0
Spiering R, Jansen MAA, Wood MJ, Fath AA, Eltherington O, Anderson AE, et al. Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis. J Transl Med. 2019;17(1):375.
pubmed: 31727095
pmcid: 6857208
doi: 10.1186/s12967-019-2128-4
Hu D, Tjon EC, Andersson KM, Molica GM, Pham MC, Healy B, et al. Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells. Proc Natl Acad Sci USA. 2020;117(48):30639–48.
pubmed: 33203678
pmcid: 7720234
doi: 10.1073/pnas.2007935117
Marro BS, Ware BC, Zak J, de la Torre JC, Rosen H, Oldstone MB. Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-α signaling. Proc Natl Acad Sci USA. 2017;114(14):3708–13.
pubmed: 28325871
pmcid: 5389329
doi: 10.1073/pnas.1700878114
Vazquez-Mateo C, Collins J, Fleury M, Dooms H. Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD mice. BMC Immunol. 2017;18(1):18.
pubmed: 28356069
pmcid: 5372316
doi: 10.1186/s12865-017-0201-4
Mbongue JC, Rawson J, Garcia PA, Gonzalez N, Cobb J, Kandeel F, et al. Reversal of new onset type 1 diabetes by oral salmonella-based combination therapy and mediated by regulatory T-cells in NOD mice. Front Immunol. 2019;10:320.
pubmed: 30863412
pmcid: 6400227
doi: 10.3389/fimmu.2019.00320
Martins CP, New LA, O’Connor EC, Previte DM, Cargill KR, Tse IL, et al. Glycolysis inhibition induces functional and metabolic exhaustion of CD4(+) T cells in type 1 diabetes. Front Immunol. 2021;12: 669456.
pubmed: 34163475
pmcid: 8216385
doi: 10.3389/fimmu.2021.669456
Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol. 2011;163(7):1507–19.
pubmed: 21449980
pmcid: 3165959
doi: 10.1111/j.1476-5381.2011.01379.x
Kozela E, Juknat A, Gao F, Kaushansky N, Coppola G, Vogel Z. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. J Neuroinflamm. 2016;13(1):136.
doi: 10.1186/s12974-016-0603-x
Subedi S, Gong Y, Chen Y, Shi Y. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Dev Ther. 2019;13:2491–502.
doi: 10.2147/DDDT.S200147
Yu Y, Chen Z, Wang Y, Li Y, Lu J, Cui L, et al. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis. Int Immunopharmacol. 2021;96: 107722.
pubmed: 33965878
doi: 10.1016/j.intimp.2021.107722
Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004.
pubmed: 27192565
pmcid: 4942846
doi: 10.1016/j.immuni.2016.05.001
Zhang T, Wang J, Zhou X, Liang R, Bai Q, Yang L, et al. Increased expression of TIGIT on CD4+ T cells ameliorates immune-mediated bone marrow failure of aplastic anemia. J Cell Biochem. 2014;115(11):1918–27.
pubmed: 24905442
Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, et al. Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol. 2018;200(8):3000–7.
pubmed: 29500245
doi: 10.4049/jimmunol.1700407
Yue C, Gao S, Li S, Xing Z, Qian H, Hu Y, et al. TIGIT as a promising therapeutic target in autoimmune diseases. Front Immunol. 2022;13: 911919.
pubmed: 35720417
pmcid: 9203892
doi: 10.3389/fimmu.2022.911919